Eli Lilly reported robust Phase 2 results for its amylin receptor agonist eloralintide, with some cohorts reaching approximately 20% mean weight loss at 48 weeks and a tolerability profile Lilly says is improved versus comparators. The company plans to move the program into Phase 3 next month following the data presentations at ObesityWeek. Findings showed dose‑dependent efficacy and lower rates of typical gastrointestinal adverse events with slower titration; Lilly highlighted the data as justification to accelerate a pivotal program competing in an increasingly crowded next‑generation obesity field.